AML is the most commonly described malignancy harboring concurrent IDH1 and IDH2 mutations, with a frequency of 0.5% to 5.7% of all IDH-mutated AML cases [22,23,24,25]. The gene discussed is IDH2; the disease is acute myeloid leukemia.